NCI CAM News Now Available

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

The VIALE-A trial showed high activity with revumenib plus azacitidine and venetoclax for patients with NPM1m/KMT2Ar AML.

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD

June 9th 2025

FDA Grants Fast Track Designation to RAD101 Imaging for Brain Metastases

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

Tim Cortese

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

The developer plans to share topline results for RAD101 in various solid tumors from the supporting phase 2b trial in the second half of 2025.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD

June 5th 2025

Encorafenib Combo May Limit Recurrence Risk in BRAF V600+ Melanoma

Experts weigh in on the practical applications of PSMA PET imaging

Phase 3 data demonstrate the potential utility of BRAF/MEK inhibition in the adjuvant setting for patients with stage IIB/IIC BRAF V600–mutant melanoma.

Ashley Chan

FDA Approves Zanubrutinib Tablets in Multiple Hematologic Indications

Phase 3 data demonstrate the potential utility of BRAF/MEK inhibition in the adjuvant setting for patients with stage IIB/IIC BRAF V600–mutant melanoma.

Zanubrutinib tablets were found to have the same efficacy and safety as capsules based on 2 single-dose, open-label randomized phase 1 studies.

Roman Fabbricatore

Revumenib Plus Azacitidine/Venetoclax Appears Safe in Older NPM1/KMT2Ar AML

Zanubrutinib tablets were found to have the same efficacy and safety as capsules based on 2 single-dose, open-label randomized phase 1 studies.

Related Content

Ariana Pelosci

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

The VIALE-A trial showed high activity with revumenib plus azacitidine and venetoclax for patients with NPM1m/KMT2Ar AML.

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD

June 9th 2025

FDA Grants Fast Track Designation to RAD101 Imaging for Brain Metastases

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

Tim Cortese

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

The developer plans to share topline results for RAD101 in various solid tumors from the supporting phase 2b trial in the second half of 2025.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD

June 5th 2025

Encorafenib Combo May Limit Recurrence Risk in BRAF V600+ Melanoma

Experts weigh in on the practical applications of PSMA PET imaging

Ashley Chan

FDA Approves Zanubrutinib Tablets in Multiple Hematologic Indications

Phase 3 data demonstrate the potential utility of BRAF/MEK inhibition in the adjuvant setting for patients with stage IIB/IIC BRAF V600–mutant melanoma.

Roman Fabbricatore